Perrigo Gains 180-Day Exclusivity With ANDA Approval For Omeprazole Magnesium PPI
This article was originally published in The Tan Sheet
Executive Summary
Perrigo receives approval for its ANDA for a Prilosec OTC equivalent and another for a generic of Advil Fast Relief. The firm includes those products in its outlook for $1 billion in new product sales over three years.
You may also be interested in...
Perrigo Nutritional Portfolio Grows As Supplement Business Sale Proceeds
Perrigo launches the first generic of Abbott's Ensure Glucerna nutritional shake. The launch could be seen as another potential jolt to lift Perrigo's share price out of a year-long fall that began when Mylan opened its unsuccessful hostile takeover.
Mylan Stretches Games Clock, Adds To Costs For Perrigo Takeover Play
Perrigo says Mylan shows “desperation” in targeting approval by 50% of its shareholders rather than the 80% approval it initially stated in its regulatory filing. A 50% threshold means Mylan would pay more in interest to lenders because it would be required to continue its takeover attempt longer than initially planned.
Mylan Stretches Games Clock, Adds To Costs For Perrigo Takeover Play
Perrigo says Mylan shows “desperation” in targeting approval by 50% of its shareholders rather than the 80% approval it initially stated in its regulatory filing. A 50% threshold means Mylan would pay more in interest to lenders because it would be required to continue its takeover attempt longer than initially planned.